Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, B-Cell, Marginal Zone 12Lymphoma, Mantle-Cell 6Lymphoma, Large B-Cell, Diffuse 4Recurrence 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

venetoclax 29obinutuzumab 21acalabrutinib 19Specimen Handling 19ibrutinib 16Cyclophosphamide 15Biopsy 15pirtobrutinib 14zanubrutinib 12fludarabine 12Rituximab 12Magnetic Resonance Spectroscopy 10Bendamustine Hydrochloride 5Stem Cell Transplantation 4Blood Component Removal 4ARQ531 4idelalisib 3fludarabine phosphate 3Whole-Body Irradiation 3Mycophenolic Acid 3tocilizumab 2polatuzumab vedotin 2Watchful Waiting 2Sirolimus 2Prednisone 2Pneumococcal Vaccines 2Lisaftoclax 2Leukapheresis 2Hematopoietic Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Lymphocytic, Chronic, B-Cell × orelabrutinib × Clear all
NCT06958705 2025-11-25

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
79 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡